US Patent 11254652 Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
Patent 11254652 was granted and assigned to Agios Pharmaceuticals on February, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 13 Dec, 2023
Golden AI
Edits made to:
Article (+360 characters)
Article
Patent abstract
Provided herein are amorphous and crystalline hemisulfate salt forms of the formula (I). Also provided are pharmaceutical compositions comprising the amorphous and crystalline hemisulfate salt forms, methods for their manufacture, and uses thereof for treating conditions associated with pyruvate kinase such as e.g., pyruvate kinase deficiency.
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Jacob P. Sizemore0
Liting Guo0
Mahmoud Mirmehrabi0
Yeqing Su0
Edits on 19 Jul, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 23 Feb, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 11254652 Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11254652
Date of patent
February 22, 2022
Patent application number
16765456
Date Filed
November 21, 2018
Patent primary examiner
Find more entities like US Patent 11254652 Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
